Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
about
Effects of nicotine exposure on in vitro metabolism of chlorpyrifos in male Sprague-Dawley ratsImpact of repeated nicotine and alcohol coexposure on in vitro and in vivo chlorpyrifos dosimetry and cholinesterase inhibitionUrinary hexane diamine to assess respiratory exposure to hexamethylene diisocyanate aerosol: a human inhalation studyRacial differences in exposure to environmental tobacco smoke among children.Evidence for concurrent effects of exposure to environmental cadmium and lead on hepatic CYP2A6 phenotype and renal function biomarkers in nonsmokers.Converging findings from linkage and association analyses on susceptibility genes for smoking and other addictions.Transgenerational exposure to environmental tobacco smokeHeterologous expression of active human uridine diphosphate glucuronosyltransferase 1A3 in Chinese hamster lung cells1,3-Butadiene exposure and metabolism among Japanese American, Native Hawaiian, and White smokers.Phenotypic CYP2A6 variation and the risk of pancreatic cancer.Comparison between objective measures of smoking and self-reported smoking status in patients with asthma or COPD: are our patients telling us the truth?Environmental tobacco smoke and children's health.Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes.Catalytic mechanism of cytochrome P450 for N-methylhydroxylation of nicotine: reaction pathways and regioselectivity of the enzymatic nicotine oxidation.Past and future applications of CYP450-genetic polymorphisms for biomonitoring of environmental toxicants.Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer.Nicotinic receptors containing the alpha7 subunit: a model for rational drug design.Exposure to the carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in smokers from 3 populations with different risks of lung cancer.Smoking and atherosclerotic cardiovascular disease: part IV: genetic markers associated with smoking.Cytochrome P450 variations in different ethnic populations.Transcriptional regulation of human UDP-glucuronosyltransferase genes.Evaluation of biomarkers of exposure and potential harm in smokers, former smokers and never-smokers.Catalytic mechanism of cytochrome P450 for 5'-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity.Fundamental reaction pathways for cytochrome P450-catalyzed 5'-hydroxylation and N-demethylation of nicotine.Human blood concentrations of cotinine, a biomonitoring marker for tobacco smoke, extrapolated from nicotine metabolism in rats and humans and physiologically based pharmacokinetic modeling.Forearm endothelial response in smokeless tobacco users compared with cigarette smokers and nonusers of tobacco.An In Silico Method for Screening Nicotine Derivatives as Cytochrome P450 2A6 Selective Inhibitors Based on Kernel Partial Least Squares.Cytochrome p450 metabolism of betel quid-derived compounds: implications for the development of prevention strategies for oral and pharyngeal cancers.Association of internal smoking dose with blood DNA methylation in three racial/ethnic populations
P2860
Q23920791-34A0FAAC-0C77-490D-B1F8-4D9D41C3C158Q23920793-AC0974ED-461A-403D-A31A-7D10FF4D76C6Q23924090-9E6F7493-E161-4269-A0CA-4CD5D94B85B0Q24811699-887CBB1E-3E0F-4381-847A-B863594ED8BBQ24816188-D1ED202C-B2AC-4459-A7ED-5BF567D6DE96Q30276828-EC37871D-7451-423E-A78D-D71308FD0C95Q33963909-CF81F452-F8C7-4201-A84A-B519A5DD4C53Q34382432-6B5BD38E-9214-497C-A99C-13D4AD633FB1Q34452819-6E7C2994-4663-4C90-8939-2C23995DE0D2Q35428436-379313F6-21BA-4CC2-AA7E-87C3B3AAF006Q35597791-DABDC196-AE48-4AC2-BF63-8BAC587D2D40Q35778367-C1698369-826F-4AB4-80FC-B133E936DBD1Q35873687-EB8A52A0-9AC7-4D1E-B020-E55DC8ABFD05Q36747874-14E0EC5E-13D8-4141-8C69-559301AEC7A8Q37000474-F8FDD742-0F1D-4629-A4BE-FC0A42B59CC6Q37008114-A3B0B0CE-CA12-437A-A93A-56AF23FEDA48Q37347201-49F20694-016A-48E1-9987-C85C313F7302Q37426846-F15A7B75-C816-4BA5-856A-7A801029A013Q37734433-91ACD058-4D21-4F6D-89F6-AA0DB1FAB2B2Q37979866-6C39953A-6ECC-4C75-9564-1A0DBB11D237Q38261875-B09F373D-928D-4917-9C94-CED7E9455C9BQ39955695-EE8D6B32-7DE2-480B-8A0D-6E845DE13BBEQ41836815-BF79750C-1FF7-4519-A64B-AC53ABAEEE7EQ42086924-AF5FF785-9A91-4834-A536-8AF396F11843Q42410356-D5669FC1-08F6-4228-8C3E-703812E4F9E9Q44551299-67A4A57D-634C-4BE0-A344-DFA23B755A2CQ46731625-43D6F83A-733D-44C6-BB57-9D29330B4D53Q51370536-A02B2D05-287D-4988-98D7-B26AB8DD17B9Q58713713-3CA74C12-B90E-4FED-AD7D-588BE1813C8A
P2860
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
@ast
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
@en
type
label
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
@ast
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
@en
prefLabel
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
@ast
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
@en
P1433
P1476
Nicotine metabolism, human drug metabolism polymorphisms, and smoking behaviour.
@en
P2093
Anthony R Tricker
P304
P356
10.1016/S0300-483X(02)00513-9
P407
P577
2003-02-01T00:00:00Z